A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

Completed · Phase 2

Conditions studied: Social Anxiety Disorder, Anxiety Disorders

In brief

The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder

Key facts

Study ID

NCT00273039

Run by

GlaxoSmithKline

People needed

242

Starts

2005-08-01

Expected to finish

2006-09-01

Last updated by the study team

2016-10-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with Generalized Social Anxiety Disorder as the primary diagnosis.
• If female, must commit to consistent and correct use of an acceptable method of birth control.

You may not qualify if…

• Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening.
• Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder.
• Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal.
• Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months.
• Patients with an unstable medical disorder.
• Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study.
• Patients who are taking other psychoactive medications.

Where it is running

• GSK Investigational Site — Beverly Hills, California, United States
• GSK Investigational Site — Burbank, California, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Miami, Florida, United States
• GSK Investigational Site — North Miami, Florida, United States
• GSK Investigational Site — Orlando, Florida, United States
• GSK Investigational Site — Smyrna, Georgia, United States
• GSK Investigational Site — Oakbrook Terrace, Illinois, United States
• GSK Investigational Site — Rockville, Maryland, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Oklahoma City, Oklahoma, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Lake Jackson, Texas, United States
• GSK Investigational Site — Buenos Aires, Buenos Aires, Argentina
• GSK Investigational Site — La Plata/Buenos Aires, Buenos Aires, Argentina
• GSK Investigational Site — Córdoba, Córdoba Province, Argentina
• GSK Investigational Site — Buenos Aires, Argentina
• GSK Investigational Site — Edmonton, Alberta, Canada
• GSK Investigational Site — Kelowna, British Columbia, Canada
• GSK Investigational Site — Miramichi, New Brunswick, Canada
• GSK Investigational Site — Providencia / Santiago, Región Metro de Santiago, Chile
• GSK Investigational Site — Santiago, Región Metro de Santiago, Chile
• GSK Investigational Site — San José, Provincia de San José, Costa Rica
• GSK Investigational Site — San José, Costa Rica

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.